← All trials
NCT05010421
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 2, 2021
- Primary completion
- Jul 31, 2023
- Completion date
- Nov 30, 2023
- First posted
- Aug 18, 2021
- Last posted
- Nov 4, 2021
- Enrollment
- 198
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ruhr University BochumLead sponsor
- Ruhr University BochumReponsible party - principal investigator
- Ruhr University BochumOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.